Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome + 5-FU/LV in 2L Pancreatic Cancer
NCT05074589Phase 3Completed
- Sponsor
- Hengrui
- Start
- Jan 2018
- Primary completion
- Nov 2021
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan liposome in pancreatic cancer (PC), sponsored by Hengrui. Started Jan 2018; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05074589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074589.